Showing 2961-2970 of 3315 results for "".
- Senate Democrats Demand $25 Billion for Widespread COVID-19 Vaccine Distributionhttps://modernod.com/news/senate-democrats-demand-25-billion-for-widespread-covid-19-vaccine-distribution/2478013/Senate Democrats want to pass legislation that provides $25 billion to ensure a potential COVID-19 vaccine is heavily distributed among the U.S. population, according to a FierceHealthcare
- Arctic Vision Announces $32 Million in Series A to Expand and Develop Ophthalmology Pipelinehttps://modernod.com/news/arctic-vision-announces-32-million-in-series-a-to-expand-and-develop-ophthalmology-pipeline/2478009/Arctic Vision, a clinical-stage biotechnology company incubated by Nan Fung Life Sciences and Pivotal BioVenture Partners China in 2019, announced its $32 million Series A financing led by Morningside Ventures, together with its existing investors. Arctic Vision focu
- EyePoint Pharmaceuticals Names Jay S. Duker, MD, Chief Strategic Scientific Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-names-jay-s-duker-md-chief-strategic-scientific-officer/2478005/EyePoint Pharmaceuticals announced the appointment of Jay S. Duker, MD, as Chief Strategic Scientific Officer. In this newly created role, Dr. Duker will lead the strategic advancement of our research and development efforts, beginning with our lead development candidate EYP-1901 for wet age-rela
- Schwind Receives CE Mark Approval for the Schwind ATOS Femtosecondhttps://modernod.com/news/schwind-receives-ce-mark-approval-for-the-schwind-atos-femtosecond/2478006/Schwind eye-tech-solutions announced that it has received CE Mark approval for the Schwind ATOS femtosecond laser. This enables refractive surgeons to offer their patients SmartSight, the latest generation of lenticul
- GenSight Biologics Reports Sustained Efficacy and Safety Among LHON Patients 3 Years After Lumevoq Treatmenthttps://modernod.com/news/gensight-biologics-reports-sustained-efficacy-and-safety-among-lhon-patients-3-years-after-lumevoq-treatment/2477972/GenSight Biologics reported that Leber Hereditary Optical Neuropathy (LHON) subjects treated with Lumevoq experienced sustained efficacy and safety 3 years after a single injection with the gene therapy. These findings come from CLIN06, the long-term follow-up study to which participants in the R
- HHS: COVID-19 Testing Reaching Capacity at Some Labs as States Grapple With Spikeshttps://modernod.com/news/hhs-covid-19-testing-reaching-capacity-at-some-labs-as-states-grapple-with-spikes/2477964/Some laboratories across the country are reaching or near capacity on COVID-19 testing as cases start to rise to record levels in some states, according to a FierceHealthcare
- Santen and NTC Announce Positive Outcome of European Decentralised Procedure (DCP) for Ducressa Post-Cataract Surgery Antibiotic/Steroid Combinationhttps://modernod.com/news/santen-and-ntc-announce-positive-outcome-of-for-ducressa-post-cataract-surgery-antibiotic-steroid-combination/2477944/Santen EMEA and NTC, have announced the completion and positive outcome of the European Decentralised Procedure (DCP) for a fixed dose combination of levofloxacin and dexamethasone (Ducressa), offering reduced exposure to antibiotics following cataract surgery.1 Levofloxacin is a broa
- The FDA Does Not Approve Allergan’s Wet AMD Drug Candidate Abicipar Pegolhttps://modernod.com/news/allergan-and-molecular-partners-receive-complete-response-letter-from-fda-on-biologics-license-application-for-abicipar-pegol/2477937/Citing an unfavorable benefit-risk ratio, the FDA rejected Allergan and co-developer Molecular Partners’ wet AMD drug candidate Abicipar pegol. The FDA issued a complete response letter to the biologics license application (BLA) for Abicipar pegol, a novel, investigational DARPin the
- Sight Sciences Names New Chief Operating Officer and General Counselhttps://modernod.com/news/sight-sciences-names-new-chief-operating-officer-and-general-counsel/2477930/Sight Sciences announced two key hires: Sam Park, joining as Chief Operating Officer, and Jeremy Hayden, who joins as General Counsel and Chief Compliance Officer. “We are excited to be able to add leaders with the outstanding track records of Sam and Jeremy as Sight Sciences continu
- AsclepiX Therapeutics Announces $35 Million Series A Financinghttps://modernod.com/news/asclepix-therapeutics-announces-35-million-series-a-financing/2477929/AsclepiX Therapeutics announced that it has closed a $35 million Series A financing to fund phase 1/2a clinical trials of AXT107, the company’s lead investigational drug, for the treatment of diabetic macular edema (DME), wet age-related macular degeneration (AMD) and macular edema secondary to r